SENXUAN(BJ:830946)2025-02-27 12:35Financial Performance - The company reported a total revenue of ¥537,136,066.43 for the reporting period, representing a decrease of 8.89% compared to the previous year[3] - The net profit attributable to shareholders was ¥122,775,968.62, down 8.73% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥115,738,710.97, reflecting a decline of 9.66% compared to the same period last year[3] - Basic earnings per share decreased to ¥0.2876, down 8.73% from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were ¥1,352,068,923.10, an increase of 1.87% year-on-year[3] - Shareholders' equity attributable to the company increased by 4.79% to ¥1,190,381,241.77[3] Market Factors - The decline in revenue and profit was primarily due to price drops in anti-tumor raw materials influenced by centralized procurement[5] Product Development - The company launched two new raw materials, Letermovir and Indocyanine Green, which generated commercial orders during the reporting period[5] Strategic Focus - The company focused on internal optimization, cost reduction, and enhancing product competitiveness to stabilize revenue and gross profit[5] Financial Caution - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[6]